Functional genomics of cardiovascular disease risk by Kim, Jin Hee



























In Partial Fulfillment 
of the Requirements for the Degree 
Master in the 












COPYRIGHT 2013 BY JINHEE KIM

























Dr. Dr. Greg Gibson, Advisor 
School of Biology 
Georgia Institute of Technology 
 
Dr. Soojin Yi 
School of Biology 
Georgia Institute of Technology 
 
Dr. Melissa Kemp 
School of Biomedical Engineering 



































 I wish to express my sincere appreciation to my advisor Dr. Greg Gibson for his 
guidance, encouragement and support. He has been a generous supervisor, a heartening 
teacher and a thoughtful friend to me. He enabled me to successfully complete my thesis. 
I could not have asked for a better mentor, teacher and guide. I would like to thank my 
committee members, Dr. Melissa Kemp, Dr. Fredrik Vannberg, and Dr. Soojin Yi for 
their guidance and feedback on my research. This thesis could never have been 
completed without their encouragement.  
 
 I would like to thank all my lab members, especially great thanks to our lab 
manager, Dalia Arafat. She has been a good friend of mine all the time. I am also grateful 
to Linda Kippner for devoting her time for providing valuable comments. 
 
  My special thanks to my family. I would not be where I am today without their 
prayers, love, and supports. The members of New Church of Atlanta, so many to mention, 
has given me strength and comfort, especially grateful to Namin Jeong, Eunyoung Ahn, 
Youngjoo Lee, and Seungmin Lee.   
 Finally, I would like to thank my wonderful husband Mark Hongchul Sohn being 
by my side throughout this process. You are the answer to my prayer. I am blessed and I 
thank God for leading me along with your hands.  
 v 
 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS vii 
LIST OF TABLES x 
LIST OF FIGURES xi 
LIST OF SYMBOLS AND ABBREVIATIONS xii 
SUMMARY ix 
CHAPTER 
1 INTRODUCTION 1 
1.1 Gene expression study 3 
1.2 Genetics of gene expression study 7 
2 METHODS 8 
2.1 Sample acquisition and Processing 8 
2.2 Data normalization 9 
2.3 Data analyses 10 
3 RESULTS 13 
3.1 Differential expression associated with Myocardial Infarction 13 
3.2 Neutrophil and lymphocyte signaling in Myocardial Infarction 20 
3.3 Disrupted effect of genotype on expression by Myocardial Infarction 23 
3.4 Risk of death due to a cardiovascular event 26 
3.5 Absence of relationship  
 between gene expression and pharmaceutical usage  29 
3.6 Genotypic Risk scores                            31  
 vi 
4 DISCUSSION 33 
4.1 Correlation with Myocardial Infarction 33 
4.2 Predictive Transcripts of cardiac death 35 
4.3 Low power of follow-up analysis and  
 Ambiguities of calling CAD types 37 
APPENDIX A  
                  Potential Genomic markers for MI risk Prediction 38 
REFERENCES 39 
 vii 
LIST OF TABLES 
Page 
Table 1  : Functional interpretation of Blood-Informative transcriptional Axes  6 
Table 2A: Biophysical and clinical data of the CDGY Phase1 cohort 14 
Table 2B: Biophysical and clinical data of the CDGY Phase2 cohort 15 
Table 3  : Association between Axis scores and drug usage 30 
 
 viii 
LIST OF FIGURES 
Page 
Figure 1: Principal Variance Component analysis in the two phases 17 
Figure 2: Differential expression related to class of CAD 18 
Figure 3: Volcano plots of significance against difference in expression 19 
Figure 4: Replicated association of Axes of Variation with MI 21 
Figure 5: Expression QTL analyses 25 
Figure 6: Two-way hierarchical plot of Cardiac death 27 
Figure 7: Volcano plots contrasting differential expression  
 with respect to death due to MI , MI, or CAD status   28 
Figure 8: Genetic risk score of MI risk 32 
Figure 9: Association between principal component of  













Understanding variability of heath status is highly likely to be an important 
component of personalized medicine to predict health status of individuals and to 
promote personal health. Evidences of Genome Wide Association Study and gene 
expression study indicating that genetic factors affect the risk susceptibility of individuals 
have suggested adding genetic factors as a component of health status measurements.  In 
order to validate or to predict health risk status with collected personal data such as 
clinical measurements or genomic data, it is important to have a well-established profile 
of diseases.   
 The primary effort of this work was to find genomic evidence relevant to 
coronary artery disease. Two major methods of genomic analysis, gene expression 
profiling and GWAS on gene expression, were performed to dissect transcriptional and 
genotypic fingerprints of coronary artery disease. Blood-informative transcriptional Axes 
that can be described by 10 covariating transcripts per each Axis were utilized as a 
crucial measure of gene expression analysis.  
 This study of the relationship between gene expression variation and various 
measurements of coronary artery disease delivered compelling results showing strong 
association between two transcriptional Axes and incident of myocardial infarction. 244 
transcripts closely correlated with death by cardiovascular disease related events were 
also showing clear association with those two transcriptional Axes. These results suggest 
potential transcripts for use in risk prediction for the advent of myocardial infarction and 








 The growing interest in the well-being of modern people has brought on a new era 
in the health care industry. Researchers accept that we are facing challenges in making 
the transition from treating illness to promoting health [1, 2]. Understanding variability of 
heath status is highly likely to be an important component of personalized medicine to 
predict health status of individuals and to promote personal health. Health status is often 
assessed by clinical risk measurements including BMI, hypertension, high cholesterol, 
and diabetes along with several dimensions such as emotional well-being or physical 
environment [3-5]; however, evidence of Genome Wide Association Study indicating 
that genetic factors affect the risk susceptibility of individuals have suggested adding 
genetic factors as a component of health status measurements [6-8].  In order to validate 
or to predict health risk status with collected personal data such as clinical measurements 
or genomic data, it is important to have a well-established profile of diseases. Numerous 
genome-wide association studies (GWAS) that have been performed since 2007 have 
discovered genetic causes of many kinds of disease including myocardial infarction, 
rheumatoid arthritis, and diabetes. However, it remains a challenge to develop and 
standardize complex disease profile networks with various types of data, and to use these 
to practically enumerate predictive genomic markers, which can be clinically applicable 
for a specific disease. Interactive and organic health predictive factors utilizing clinical, 
metabolomic, and genomic data are desired to promote prognostic and therapeutic 
strategies. 
 Cardiovascular disease has been studied for decades, and its long-term risk factors 
are well known [9, 10]. Framingham risk scores is an established method utilized to 
predict the risk of getting heart disease such as cardiovascular disease, coronary heart 
 2 
disease, or stroke. Limitations of Framingham risk scores have been observed for with 
regards to the accuracy that it  provides in reliable heart related disease risk estimates [11, 
12]. In order to improve the accuracy of predictive risk score for heart disease, numerous 
studies have been performed, adding more predictive risk factors such as coronary artery 
calcium score, ankle brachial index or C-reactive protein [13-15]. Despite considerable 
efforts, the current list of risk factors predictive of subsequent death and occurrence of 
acute myocardial infarction is still limited.  
 Preininger et al.[16] evaluated whether clinical functions explain gene expression 
and observed 9 blood-informative Axes from total gene expression of the healthy cohorts. 
Those 9 Axes showed trends representing significant biological functions relating to 
immune status. Variation in quantitative measures along these Axes suggests that 
individuals can be discriminated with respect to their immune health. This approach will 
give informative and valuable resources for realization of personalized medicine or 
treatment [17-19].  
 Premises in this study were that different health statuses also impact peripheral 
blood genomic profiles, and these can be discriminated by 9 blood-informative Axes. In 
addition to testing these hypotheses, how genotype and gene expression are significantly 
associated, and whether they solely or jointly modulate disease risk factors were 
evaluated. In order to approach these questions, GWAS on gene expression was 
performed to evaluate how genetic factors lead to abnormalities of transcript abundance 
that are associated with cardiac disease and the regulatory polymorphism (eSNP) profiles 
between patients with cardiovascular disease and adults with no disease were examined 
to study variance of disease status in the cardiovascular disease cohort from the Emory 
Cardiology Genebank. The cardiovascular disease cohort from the Emory Cardiology 
Genebank contains 192 participants in age over 65 years (CDGY1) and an additional 
replication sample of 163 younger CAD patients (CDGY2). Each phase of cohorts 
include 43 participants and 50 participants as controls respectively. eSNP profiles 
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differences were contrasted between CAD patients and the control group and genomic 
predictors were generated based on blood-informative transcriptional Axes, gene 
expression and/or regulatory genotypes, for myocardial infarction (MI) and death by 
cardiac disease. In the course of this study, I asked in what proportions, genetic and 
environmental effects contribute to divide a population into distinct positions in immune 
space and how these immune spaces explained by Axes distinguish different statuses of 
cardiac disease from health.  
  While profiling the cardiovascular disease cohort of the Emory Cardiology 
Biobank, strong evidence of genomic variance among different classes of cardiovascular 
disease was found. This finding will open up a new possibility to identification of 
peripheral blood gene expression and regulatory genotype profile that is correlated with 
MI along with comparison profiles of CAD and normal individuals. 
1.1 Gene Expression Study 
 Peripheral blood gene expression is influenced by complex interactions of 
environmental factors along with genetic factors at baseline [20, 21]. Gene expression 
profiling has long been studied and is still used as a valuable tool for finding relationship 
between health and disease or phenotypic traits [22, 23]. Gene expression is potentially 
more informative than clinical measurements or genotypes itself, since it represents status 
of molecular mechanisms, such as level of triglyceride, cholesterol, or glucose, that can 
be attributed to health related traits. It is also influenced by different life-style of 
individuals [24]. Studies in the Gibson Lab at Georgia Tech have indicated that lifestyle, 
gender, ethnicity, and geographic location affect gene expression profile [25, 26]. Two 
previous studies in the Gibson lab, the Morocco study and the Brisbane study, showed 
gene expression clusters by geographic location between rural and urban populations 
[25], as well as variation within the urban populations studied [27]. Other authors have 
shown some evidence that the social condition of different neighborhoods can influence 
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one metric of physical phenotype, BMI, at significant p-value <0.01 in urban Canada [28] 
and at p-value <0.03 in the US [29].  Adults with low childhood socioeconomic status 
(SES) and adolescents in low SES showed significantly elevated immune markers such as 
IL5, IL6, and IFN-ɤ (p<0.05) [30, 31]. Miller et al. also observed the defensive gene 
expression in respect to resistance to glucocorticoid signaling from subjects with low-
SES background [32] . While, these studies provide evidences of how informative gene 
expression is, gene expression is not only influenced by environmental factors, but also 
by data sampling criteria, technical effects, and data normalization methods [33, 34].  
Since microarray data can be also easily biased by biological factors including age, ratio 
of genders, and ethnicity, both technical and biological effects were addressed in the 
study. 
 Peripheral blood mononuclear cells (PBMC) also include molecular signatures of 
human disease, and the gene expression of these cells has been successfully utilized in 
efforts to dissect the complexity of disease on a molecular level. Achiron and Gurevich 
reviewed peripheral blood gene expression in a model of multiple sclerosis (MS) and 
concluded that PMBC gene expression can be used as MS disease transcriptional 
fingerprints and that this will lead to better understanding of the mechanism underlying 
disease and will enable the evaluation of transcriptional biomarkers for diagnostics and 
prediction of clinical outcome [35].  Numerous studies have investigated gene expression 
in the context of heart disease. For example, cardiac markers such as GATA4, MEF2C, 
Nkx2.5/Csx revealed increased expression of mRNA up to 3.5 fold [36] and 160 genes 
correlated with the severity of coronary artery disease were found and their partial least 
square multivariate regression model showed statistically high significance in prediction 
[37] .  
 Preininger et al. observed 9 transcriptional Axes from total peripheral blood gene 
expression in a healthy cohort from the Center for Health Discovery and Well Being 
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(CHDWB) in Atlanta. Furthermore, CHDWB healthy subjects tend to fall into 8 k-means 
clusters by 9 modules.  9 modules are representative of T cells, platelets, B cells, cell 
machinery, TLR signals/interferon, and antiviral (Table 1) [16]. These findings indicate 
the importance of studying co-regulation factors in each module and of evaluating the 
results in order to find associations with cardiac disease risks. 
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Table1.  Summary and Functional Interpretation of Blood-Informative Transcriptional 
Axes. This table is encapsulated by Marcela Preininger et al. [16] 
Axis Number of genes Keyword 
1 866 T-cell signaling 
2 237 Platelets 
3 99 B-cell signaling 
4 982 Post-translational modification 
5 1028 Toll-like receptor signaling pathway 
6 550 RNA binding  
7 169 Viral response 
9 571 
RNA procession 
B cell activation 




1.2 Genetics of Gene Expression Study 
 Gene expression shows familiar aggregation and segregation patterns in humans,  
suggesting a genetic inheritance component of gene expression [38]. In general, despite 
the effect of many environmental factors such as lifestyle on the levels of gene 
expression, the trend of genetic inheritance of gene expression is relatively consistent, 
however study replication rate at the same significant cutoff has not been achieved above 
20% [39]. Whether these difficulties of replication are due to power issues or biology is 
not yet clearly identified [40], but emphasis on trends of association among different 
phases of studies is remarkably informative and sufficient to show replicability. 
 GWAS applied gene expression is a powerful tool that has been used to dissect 
genetic regulation of individual genes both in a healthy population and in a 
cardiovascular disease cohort [41, 42]. In a recent publication, Rotival et al. found 11 
clusters of expression which are influenced by SNPs (p <1.15 x10-9) from 1,490 healthy 
Europeans. The variability of the pattern was explained in range between 1.9% and 
24.8% by the lead SNPs and they found 5 patterns that were associated with different cell 
types. They also replicated 6 associations, which were independent of cell types, with 758 
subjects in the Cardiogenic study [43]; however, they only reported associations with 
SNPs of conserved modules and did not report the association with disease. In this study, 
the association of eSNPs with cardiovascular disease was proposed as a means to unravel 
abnormal gene expression patterns at specific genotypes by studying patterns of co-
expression and normal genetic regulation. New strategies of profiling genetic association 
of gene expression in cardiovascular disease and generating a genetic risk score utilizing 
abnormal genetic regulation will help to make predictions of individual risk of 







 The major purpose of this paper is to use microarray gene expression data and 
whole genome genotype data to generate gene expression profiling and regulatory 
polymorphism profiling and compare profiles of cardiovascular disease patients with 
participants with no disease. The gene expression profile of cardiovascular disease will 
be evaluated with second phase of cohort. 
2.1  Sample acquisition and Processing 
 Sample Acquisition  
 The cardiovascular disease cohort 1 consists of 192 participants recruited from the 
Emory Cardiology Genebank, a registry of patients undergoing cardiac catheterization. 
Out of 192 participants, 17 non Caucasians were excluded to address ethnicity effects on 
eQTL analysis. Subjects are ranged in age from 41 to 85, with mean of 67, and grouped 
into four different status, patients with stable CAD defined as >50% stenosis in one or 
more coronary vessels, angiographically normal, experiencing an acute MI event, and had 
a history of MI, plus follow-up information for occurrence of future adverse death and 
MI. These follow-up results were gathered between 2years and 5 years after the day of 
sample collection. These four classes of status will be designated by CAD, FINE, 
AcuteMI, and OldCAD, and called CAD status. Each class has approximated equal 
number of participants. 163 younger CAD patients who are all Caucasians were added to 
the cohort to replicate study. The second cardiovascular disease cohort includes subjects 
who are ranged in age from 26 to 83, with mean of 56. Participants are classified 
according to definition as described with the first cohort. Hereinafter the first cohort is 
referred as CDGY1(CarDioloGY Phase 1) and CDGY2(CarDioloGY Phase 2). CDGY 
 9 
cohorts are representative of Atlanta. Biophysical and clinical data of the cohorts are 
indicated in the Table1.  
 Sample Processing   
 All participants of CDGY cohorts donated peripheral blood in Paxgene tubes for 
gene expression and genotype data over a five year period. CDGY1 and CDGY2 were 
processed 12 months apart. Gene expression data was generated using hybridization of 
labeled RNA to Illumina HT-12 bead arrays with probes for all human genes. We 
consider log base 2 transformed 14,343 probes which are consistently detected across 
multiple datasets of peripheral blood samples. Genotyping was performed with Illumina 
OmniExpress SNP chip which has over 730,000 genetic markers. After quality filtering, 
there were about 610,000 markers retained in the data set. Theses markers are common 
variants, MAF larger than 0.05.  
 
 
2.2  Data normalization 
 Data normalization was a central process for this project. The recent published 
paper by Qin et al. [34] strongly implied that different normalization methods can 
crucially affect data. Failure in appropriate normalization can conceal biologically 
meaningful signals and also generate false positives by technical biased components. In 
addition, stability and replicability of normalization in other cohorts are also essential. 
Appropriate data normalization is thus a core issue in gene expression analysis.  
 Dr. John Storey recently published about new efficient normalization method 
called Supervised Normalization of Microarrays (SNM). His team showed that SNM 
method successfully separate biologically meaningful signal from unavoidable technical 
factors compared with other broadly used normalization methods [44] such as mean or 
median centered normalization, quantile normalization such as IQR, or rank ordering 
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normalization .  CDGY1 and CDGY2 gene expression data were normalized with SNM 
method to remove two technical effects, batch and RNA quality, and to adjust for effects 
of gender, ethnicity, and BMI.  Biological variable of interest, four classified CAD status, 
were statistically adjusted for optimizing biological signals and reducing noise. 
Supervised normalization of Microarray (SNM) method is implemented in the 
Bioconductor as the R package.    
 
 
2.3  Data Analyses 
 Principal component analysis and Variance component analysis 
 The first 5 principal components and the magnitude of variance were computed 
using the Basic Expression Workflow in JMP Genomics. The magnitude of variance is 
calculated as an average of the proportion of the trait explained by each principal 
component.  
 ANOVA and Volcano plots 
 Analysis of Variance (ANOVA) was performed fitting a model to data from a 
class variable in order to retain gene sets of possible effects of the selected variable in 
JMP Genomics. In this study, ANOVA was utilized to query which genes are 
differentially expressed between MI and nonMI and between cardiac-death and alive. It 
generates significance as the negative log p-value and fold-change in gene expression 




 Gene expression analysis 
 The CDGY studies for gene expression profiling applied two mathematical 
methods, a principal component analysis and a modular analysis. The PCA is a largely 
utilized method to discompose variables accounting for as much of variability in the data 
and this method generated first 5 principal components explaining  42% of variation in 
CDGY1 and  46.3% in CDGY2. The modular analysis is a methodology designed to 
support system-scale analysis of gene expression study by Chaussabel et al. [45]. They 
defined 9 Axes of variation which are strongly characterized as different types of immune 
function. Each Axis is generated by PC1 of the covarying ten defining blood informative 
transcripts.  Each PC1 is explaining approximately 75% of variation in each module. 
These Axes are characterizing where people are in immune space. 
  
 Genetic of gene expression analysis 
 GWAS applied gene expression was performed to find cis acting regulatory 
polymorphism (SNPs located within 250kb upstream or downstream of the probe) in 
CDGY1.  Cross correlation analysis in JMP Genomics was used to compute Pearson all 
pairwise correlations matrix between all 14,343 probes and 610,859 SNPs which are 
MAF >0.05 set of variables and to test their significance.  To clean SNPs which fall 
within a gene had linkage disequilibrium, a Bioconductor package, Illumina 
HumanWGDASLv4, was utilized and SNPs within probe sequence were removed from 
the SNP list.   
 To address if there are differences in cis acting regulatory effects on gene 
expression among CAD status, SNP interaction analysis was performed by fitting a 
model to ask how differently each gene expression is regulated by a SNP in each CAD 
status.  
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 Cardiovascular disease Risk Analysis 
 Two-way hierarchical cluster was performed to find signature of fatal risk by 
cardiovascular disease. Clustering was performed with 244 probes which are retained 
from ANOVA test with cardiac death index at NLP3(Negative Logarithm of Pvalue). 
Three deepest clusters were selected to see how many individuals, who died by 
cardiovascular disease related events, are falling into each cluster. PC1 of 244 probes 
were calculated and used as one of the suggested genomic risk predictors.  
 One of major goals of this study is to generate a genomic predictor of MI and fatal 
risk. Gene expression associated MI risk is driven by local regulatory polymorphism. 16 
eSNPs with MAF >0.05 associated with transcripts of cardiac death risk at p-value <10-8 
were used to generate risk score. The process of generating risk score is as follow: a) 
Find Axis explaining death by CAD (PC1 of cardiac death associated transcripts), b) 
ANOVA test in JMP Genomics with the Axis and collect the genes at p-value<10-7which 
is Bonferroni corrected p-value(alpha =0.01), c) Find eSNPs for  genes which are 
selected from ANOVA test, d) Give risk score 2 for homozygous allele for the high risk 
variant, risk score 1 for heterozygous, and risk score 0 for homozygous allele for the low 
risk variant, e) Add all 16 risk scores given by each eSNP. 
 Multi-locus genotypic risk score for blood gene expression was also generated by 
summing the number of alleles that are associated with expression of elevated expression 
in each of the Axes.  This score was generated using eSNP data from the parallel healthy 






3.1  Differential Expression associated with Myocardial Infarction 
 In order to assess whether peripheral blood gene expression associated with 
cardiovascular disease status, microarray analysis of 14,111 transcripts were performed in 
two batches of 175 and 163 participants in the Emory Cardiology GeneBank. Whole 
blood samples were collected over a five year period and those were preserved in 
PaxGene tubes. RNA was extracted 12 months apart. Anthropomorphic and clinical 
parameters are indicated in Table 2A and Table 2B.  Approximately equal numbers of 
individuals were presented who were (i) experiencing an incident of myocardial 
infarction at or within 24 hours prior to sampling, (ii) had a history of myocardial 
infarction, (iii) were diagnosed with coronary artery disease after enrolling at the clinic, 
or (iv) had no evident signs of cardiovascular disease. These are referred to as the MI, 
oldCAD, CAD, and FINE(Controls) samples respectively.  
 Raw transcript abundance measures from the Illumina BeadStudio were log base 
2 transformed and normalized with the open source algorithm Supervised Normalization 
of Microarrays (SNM). SNM normalization method were performed to remove technical 
effects of hybridization batch and RNA quality, to adjust for effects of BMI, gender and 
ethnicity (in phase 1, but all patients in phase 2 were Caucasian), and to estimate the 
extent of differential expression associated with CAD status.  The 0 estimate for both 
phases was between 60 and 70%, indicating that this proportion of the transcripts was 
unaffected by CAD status. This is however suggesting that as many as 30% of 14343 
transcripts abundance may be differentiated with respect to CAD status.   
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Table 2A.  Biophysical and Clinical Data of the CDGY Phase1 cohort 
CDGY Phase1 




CAD without MI  
(n=49) 
OLD MI  
(n=46) 
Acute MI  
(n=37) 
Age 67 ± 10 71 ± 7 72 ± 10 62 ± 7 61 ± 8 
Male (%) 64 44 63 70 81 
Systolic BP 142 ± 24 147 ± 21 146 ± 25 139 ± 23 134 ± 23 
Diastolic BP 76 ± 11 77 ± 11 75 ± 13 76 ± 11 76 ± 11 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 
Weight (kg) 87 ± 21 82 ± 23 81 ± 19 90 ± 19 95 ± 19 
BMI 29 ± 6 28 ± 7 28 ± 5 31 ± 7 31 ± 6 
Diabetes Hx (%) 37 30 24 46 51 
Hypertension Hx (%) 81 77 88 83 76 
Dyslipidemia Hx (%) 79 72 82 83 78 
Smoking Hx (%) 67 51 79 50 57 
Gensini Score 36 ± 51 1 ± 3 37 ± 47 56 ± 71 58 ± 63 
Statin Use (%) 74 58 84 74 78 
Aspirin Use (%) 75 53 84 76 86 
ARB ACE Use (%) 57 53 59 57 59 
Beta Blockers Use (%) 61 44 57 67 78 
Plavix Use (%) 52 14 65 70 57 
Dead by Card at sampling 12 1 2 6 3 
MI at sampling 37 0 0 0 37 
Dead by Card at 5 years 11 0 6 3 2 
MI at 5 years 18 4 4 4 6 
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Age 56 ± 10 54 ± 8 55 ± 5 51 ± 8 71 ± 12 
Male (%) 66 64 71 57 75 
Systolic BP 133 ± 21 134 ± 21 136 ± 22 127 ± 19 137 ± 22 
Diastolic BP 75 ± 12 76 ± 12 76 ± 12 74 ± 10 73 ± 12 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 
Weight (kg) 92 ± 24 97 ± 18 94 ± 27 90 ± 27 86 ±26 
BMI 31 ± 8 32 ± 7 31 ± 7 31 ± 9 28 ± 7 
Diabetes Hx (%) 34 16 43 40 46 
Hypertension Hx (%) 72 68 79 66 79 
Dyslipidemia Hx (%) 77 60 88 85 79 
Smoking Hx (%) 60 54 69 63 50 
Gensini Score 31 ± 51 0.3 ± 1.3 39 ± 49 53 ± 69 33 ± 34 
Statin Use (%) 71 56 83 79 67 
Aspirin Use (%) 81 64 90 96 71 
ARB ACE Use (%) 56 46 62 64 54 
Beta Blockers Use (%) 65 54 69 72 67 
Plavix Use (%) 49 8 79 64 54 
Dead by Card at sampling 2 2 0 0 0 
MI at sampling 24 0 0 0 24 
Dead by Card at 5 years 6 1 2 2 1 
MI at 5 years 0 0 0 0 0 
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5 principal components of overall gene expression variation which were computed by 
Variance component analysis in JMP Genomics, which collectively capture 
approximately 45% of the variance, indicated that CAD status explains 2.8% of these PC 
in phase1 and 4.2% in phase2, with only PC 3 significantly affected in the same direction 
in both.  Ethnicity and BMI group make stronger contributions to gene expression 
variation than CAD status. (Figure 1). 
 The mean values of PC1 to PC5 among the four CAD status samples were 
compared and indicated that the mean values of PC3 were differentiated in MI samples 
from the other three CAD status samples in both phases (Figure 2A, B), but the other 
three status samples are not significantly differentiated from each other. This was 
confirmed after an SNM data normalization on the z-scores of transcript abundance 
linearly adjusted for technical and biological covariates. ANOVA was subsequently 
performed to contrast of each samples pairwise, as well as of MI vs non-MI. Among the 
CAD and Control groups did not show significant differential gene expression, but a 
small number of transcripts were expressed differentially in the MI samples in both 
phases. Figure 3A, B, C are the volcano plots displaying the relationship between fold 
difference in abundance along the x-axis, and significance as the negative logarithm of 
the p-value (NLP) on the y-axis. Higher expression in non-MI samples are showed in the 
right arm. Differentiation in transcript abundance is biased toward up-regulation in the 
MI samples, and the effect of MI seems to be stronger in the second phase as expected 



























































































































Variance Component (CDGY2)  
  
Figure 1. Principal Variance Component analysis in the two phases.  In both cases, 85% 
of the variance among individuals is unattributed, and 2.8% is correlated with CAD status 
in phase1 and 4.2% in phase2.  Ethnicity is only a factor in Phase 1. All individuals in 
Phase 2 were Caucasian.  BMI3 refers to 3 categories of BMI (>30, Obese; >25, 
Overweight; <25 Normal).  Technical effects from Plate and Batch were adjusted and no 





Figure 2 A, B.  Differential expression related to class of CAD.  Principal component 3 
scores by class of CAD in the two phases of gene expression profiling.  Replication of 
differential expression between individuals experiencing an acute MI with meaningful P-
values from ANOVA with three degrees of freedom for the CAD class effect, whereas 
the current CAD, healthy control, and history of CAD (CAD, FINE, OLD respectively 





Figure 3 A, B, C. Volcano plots of significance against difference in expression in log2 
units of SNM-normalized data. Up-regulated genes in patients with an MI to the left, and 
down-regulated genes in MI to the right.  Transcripts at p<0.001 in phase 2 are colored.  
Almost all of transcripts show same directionality in differential expression in Phase 1 
and Phase 1 follow-up, which however showed much less evidence for significant 
differential expression in the total sample (suspecting possibility of lower technical 
quality, or unknown covariates biasing against the MI association). 
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3.2 Axes of Variation implicate altered Neutrophil and Lymphocyte signaling in 
Myocardial Infarction 
 Although there is little overlap in the identity of transcripts between phase 1 and 
phase2 that are significantly associated with MI, the differential expression is consistently 
in the same direction. Figure 3 is showing this directionality of differential expression of 
transcripts with MI. The red circles correspond to the significantly up-regulated 
transcripts in phase 2 (Figure 3B) and are biased toward up-regulation in the MI samples, 
implying a high false negative rate with a sample of fewer than 50 patients. The blue 
circles correspond to the down-regulated genes and these are uniformly down-regulated 
in phase 1. The reciprocal result is seen in phase 2 for significant transcripts of phase1. 
To explore the nature of the differential expression further, evaluation was performed 
with the nine Axes of Variation that are highly conserved in peripheral blood gene 
expression profiles from multiple studies in healthy and disease cohorts. These nine Axes 
of peripheral blood gene expression variation was recently described and showed in the 
publication of Preininger et al., [16]  
 Covariance with ten defining blood information transcripts (BIT) per Axis defines 
each Axis of Variation. PC1 of the 10 BIT capture the covariance, and these nine 
defining PCs were fit jointly by multiple linear regression to the full set of 14,343 
transcript probes in the analysis.  Over 7,000 probes associate with at least one Axis at 
Bonferroni significance (p<5.310-5), and cross-matching of the list of significant 
associations between the two phases shows on average 80% overlap, ranging from 75% 
for Axis 4 to 95% for Axis 7.  Each transcript associated with the same Axis in both 
phases was classified as an Axis gene, and we plot the means of the transcript abundance 





   
Figure 4 A, B.  Replicated association of Axes of Variation with MI.  Each dot is 
represented each gene that is correlated with one of the 9 Axes in both phases. The plots 
are showing the mean difference between individuals experiencing an MI and nonMI at 
sampling (higher expression in MI producing negative values).  The overall relationship 
of the Axes with MI status is highly replicated, particularly notably showing down-
regulation of Axis 1 and up-regulation of Axis 5.  The difference between the studies in 
Axis 2 is readily explained because this Axis associated with BMI, which is elevated in 
the phase 2 samples.  
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             Unambiguous down-regulation of genes in Axis1 and up-regulation of genes in 
Axis5 show the concordant directionality of effects between the two phases. The PC1 
scores for these two Axes genes are negatively correlated in this and other studies, 
because they are partially correlated with lymphocyte (Axis 1) and neutrophil (Axis 5) 
counts respectively. Cell counts are not available in this cohort, but the data is 
nevertheless consistent with up-regulation of neutrophil-related gene expression in 
patients experiencing an MI.  The data does not distinguish whether this reflects a 
predisposition to MI in patients with high neutrophil counts, or an increase in neutrophil 
counts during MI, both of which have been documented in the literature. 
 There is an independent evidence for neutrophilia explaining some of the high 
Axis 5 expression in MI patients. This comes from cross-matching of the Axis 5 genes 
with genes known to be neutrophil-enriched from published gene expression profiles of 
distinct blood types.  46 percent of 2,469 genes which is known to be neutrophil-enriched 
are associated with Axis 5 in this study, and 55 percent of the 2,042 Axis 5 genes are 
neutrophil-enriched.  However, it is possible that differential neutrophil abundance is not 
simply explains the differential expression, since the overlap is only partial. Similarly, 
reduced lymphocyte abundance does not solely explain the low Axis 1 scores in MI 
patients, because T-lymphocyte abundance is strongly associated with only 44 percent of 
3,584 Axis 1 genes. Furthermore, gene ontology analysis suggest that genes in Axes 8 
and 9 are also involved in aspects of T-cell signaling, while Axis 3 has an excess of genes 
annotated to B-cell signaling.  These results lead to the conclusion that differential gene 
expression in MI patients is largely attributable to elevation of the ratio of neutrophils to 




3.3  MI disrupts the effect of genotype on expression of a fraction of genes in 
peripheral blood 
 eQTL analysis was performed and found further evidence for differential 
expression. As described in the method, non-Caucasian samples were excluded and 153 
Caucasian samples were remained for eQTL analysis to prevent the possible influence of 
population stratification between Caucasian, African, and Asian American samples. The 
genotypes of over 600,000 common polymorphisms with a minor allele frequency <0.05 
were obtained and local regulatory effects of theses SNPs on abundance of transcripts 
was computed utilizing Pearson correlation method in the phase1 samples. Only cis-
eSNPs which are located within 250kb were included in the profile. eSNP profiles of 
associations were filtered subsequently to remove all known common SNPs within the 
probes in this study and in high linkage disequilibrium (r2 > 0.5) with them.  
 Local genetic regulation of transcript abundance was detected for 355 probes 
representing 334 genes at p<10-5, with a q-value false discovery rate of just 1%.  87% of 
these eSNP effects replicated in a parallel healthy adult cohort that we are also studying 
in Atlanta, implying that they are robust eQTL in adult peripheral blood samples.  
Interestingly, 5% of all transcripts are Axis 5 genes, but only 0.5% of eSNPs were 
observed in Axis5 genes, implying significant under-representation of Ais5 genes with 
eSNPs. On average, each eSNP explains 11% of the abundance of the associated 
transcript, with a range from 5% to 45%, as observed in other studies. 
 Linear regression was performed to evaluate whether MI status influences local 
genetic effects, fitting transcript abundance as a function of genotype, MI status, and the 
interaction between them.  78 significant interaction effects were observed at p<0.05, 
more than expected by chance, but only a handful at experiment-wide significance. In 
order to confirm this result, MI samples were removed and eQTL analysis on just the 120 
non-MI Caucasian samples was performed again.  This resulted in the loss of 95 
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significant associations as expected due to the reduced power in a smaller sample, but 
also led to the detection of an additional 45 associations at p<10-5, as shown in Figure 
5A. . 36 cases show significant interaction effect between genotype and MI status. Each 
case did not show any significant relationship between genotype and gene expression in 
the MI samples where a highly significant on exists in the non-MI samples (Figure5B) 
By contrast, an interaction effect with a modest increase of MI status on the genotypic 
effect was shown in only 6 out of the 50 cases of reduced significance in the non-MI 
samples (Figure 5C). 
 MI reduced the genetic regulation of expression of a subset of genes. This result 
could be simply explained that the eSNP effect is diluted out in the MI samples where 
neutrophils are more prevalent if the eSNP effect is predominately observed in 
lymphocytes or monocytes. To exclude this explanation, an equal number of non-MI 
whose Axis5 values are high was removed from the phase1 and eSNP profiling was re-
performed. As a result, only a handful of cases showed increased significance below the 
p<10-5, nevertheless significance was reduced for 100 genes due to the loss of power by 
reducing the size of the study. 
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Figure 5 A, B, C, D, E. Expression QTL analyses. (A,B) Plot of significance (negative 
log P, NLP) of cis eSNPs with a transcript probe located within 250kb of the SNP, 
contrasting the All Caucasian sample in Phase 1 with the same sample excluding 
individuals experiencing an MI. (A) Shows the full range of NLP, and (B) eSNPs in the 
range 5 < NLP < 15.  Colored points differ between the full and no-MI samples by at 
least 0.5 NLP units, red indicating higher significance in the nonMI sample, and blue 
higher significance in the full sample (ALL). (C) Shows the same analysis as (B) but 
missing 37 individuals with the highest Axis 5 scores who were not experiencing an MI.  
Numbers show the number of eSNPs in the red and blue categories across the full range 
of NLP > 3. (D,E) Representative plots of transcript abundance by genotype, colored with 
respect to MI status (red experiencing an MI, blue no-MI).   Lines show the slope of the 
two classes, indicating an interaction effect in (D) but no interaction effect in (E). 
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3.4  Risk of death due to a cardiovascular event may also associate with the Axes 
of Variation 
 In the phase 1 sample, 12 individuals had died of a verified heart attack or stroke 
at sampling and 10 individuals during 5 years of period. Analysis of variance contrasting 
the MI samples with the remainder revealed 244 transcripts significantly differentially 
expressed at p<10-3.  Two-way hierarchical clustering of these transcripts (Figure 6A,B) 
reveals 3 groups of genes that are clearly co-expressed and distinguish the patients who 
died subsequent to donation of a sample to the Cardiology GeneBank.  The first principal 
component of the 244 significantly differentiated transcripts is predictive of death-due-to-
CVD with an AUC 0.80 (Figure 6C).  This result was unambiguously replicated in the 
phase 2 with 8 patients have subsequently died with an AUC over 0.75 (Figure 6D). 
 The differential expression associated with death appears to involve the same 
components of variation as the MI-associated genes.  PC1 for the three clusters in Figure 
6A are highly correlated with the PC1 scores for Axes 1 and 5, even though the identities 
of the highly significant genes are distinct from the MI-associated genes (Figure7A,B).  If 
the 5 patients who were experiencing an MI and subsequently died due to a second event 
are removed from the analyses, the correspondence between ‘death-related’ gene 
expression and ‘MI-related’ gene expression remains since the up-and down-regulated 
transcripts are still associated with Axes 5 and 1 respectively (Figure 7D).  This result 
implies that peripheral blood gene expression profiles that are associated with MI may 
also predict likelihood of risk of death due to a cardiovascular event, but we caution that 





Figure 6 A, B, C, D. Two-way hierarchical plot of normalized transcript abundance 
(columns) by individual participant (rows), highlighting the three deepest clusters.  The 
left column indicates individuals who have had an MI during the 5 year period since 
enrolling at the clinic and who have subsequently died of an acute MI or stroke.  (A) Note 
that 7 of the latter are in the 32 person blue cluster in phase1. (B) Two-way hierarchical 
plot was generated in phase2 with same transcripts in phase1. Three deepest clusters were 
highlighted. Similarly, blue cluster includes 6 persons out of 8 total individuals who have 
died by an MI or stroke. Efficient of this model was represented as ROC curve, with 





Figure 7 A, B, C, D, E.  Volcano plots contrasting differential expression with respect to 
death due to MI , MI, or CAD status. Colored points are significant in (A) at NLP>3 
showing all in the same direction with (B), (D), (E), but there is only a weak, non-
significant trend in the CAD versus healthy control contrast in (A). Red circles are up-
regulated in the 23 individuals who were confirmed to have died of a cardiac event. 
Down-regulated transcripts were marked as blue circles. (D) Shows the differential 
expression in just the 18 participants who died of a cardiovascular event but were not 
experiencing an MI, and all other non-MI individuals.  
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3.5  Absence of relationship between gene expression and pharmaceutical usage 
of measures of CAD 
 Association of pharmaceutical usage with gene expression in the cohort was also 
assessed. One-way ANOVA analyses show no significant enrichment for gene expression 
by prescription status for Statins, Beta Blockers, Plavix, or self-reported Aspirin usage. 
However, significant association between Axis scores (PC1 of the blood informative 
transcripts) and Plavix usage or Beta-Blockers was observed in both phases, of which the 
effects were nevertheless not replicated in both studies (Table 3). Thus, it is most likely 
that they are due to confounding of the covariance of gene expression in each Axis with 
unidentified biological factors that may have been common in the drug groups. 
Alternatively, the factors that were not captured in our analysis such as effects from 
dosage, prescription interval, or patient compliance are accountable for that drugs 
influence gene expression.  
 Similarly, relationship between gene expression and angiographic measures of 
coronary function was also not detected. For example, Gensini index showed large 
variability as expected of a cardiology cohort that includes non-CAD individuals and 
patients with long-term CAD, but was not correlated with any of the Axes of Variation 
and further had no significant association with individual transcripts. One measure, the 
count of putative progenitor cells (VEGF+, CD44+) in peripheral blood, showed a 
notable tendency toward significant association, however were too small fraction of the 
total cell counts  and thus could not be directly associated with total blood gene 
expression. 
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Table 3. Association between Axis scores (PC1 of the blood informative transcripts) and 
drug usage 
CDGY Phase1 ARB_ACE Aspirin BB Plavix Statin 
snmAxis1 0.1836 0.3797 0.026 0.1779 0.7524 
snmAxis2 0.5009 0.8026 0.1032 0.0224 0.4118 
snmAxis3 0.0718 0.7499 0.9961 0.1101 0.8972 
snmAxis4 0.8347 0.1061 0.4121 0.0032 0.1836 
snmAxis5 0.0346 0.6337 0.0441 0.1246 0.667 
snmAxis6 0.2781 0.0678 0.1541 0.1086 0.4888 
snmAxis7 0.7535 0.4342 0.495 0.0483 0.1524 
snmAxis8 0.7412 0.0215 0.7177 0.6603 0.0173 
snmAxis9 0.7349 0.7014 0.0558 0.0282 0.4024 
snmAxis10 0.1115 0.2117 0.0255 0.6889 0.3016 
 
CDGY Phase2 ARB_ACE Aspirin BB Plavix Statin 
snmAxis1 0.1034 0.0825 0.3247 0.0361 0.541 
snmAxis2 0.158 0.5095 0.1991 0.5845 0.8628 
snmAxis3 0.1425 0.6631 0.3242 0.9502 0.7558 
snmAxis4 0.7504 0.7459 0.8229 0.6265 0.9286 
snmAxis5 0.5094 0.1245 0.5751 0.0431 0.4936 
snmAxis6 0.6511 0.9084 0.2751 0.6245 0.5517 
snmAxis7 0.7223 0.6653 0.3923 0.6767 0.6182 
snmAxis8 0.7105 0.8915 0.3309 0.7893 0.3877 
snmAxis9 0.6234 0.5218 0.3063 0.1517 0.9016 
snmAxis10 0.6352 0.1897 0.8721 0.0417 0.328 
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3.6  Genotypic Risk scores 
 Genome-wide association study has identified 16 significant SNPs that are 
reproducibly associated with the cardiac death index. Differentiation between the MI 
samples for the Control was only modest when using a multi-locus genotypic risk score 
that was generated by summing the number of risk alleles in each person in phase 1. The 
amount of variance in coronary disease explained was low (Figure 8 A,B), indicating that 
score generated in this way has low predictive ability in follow up MI. Although it was 
associated with the expression of a subset of genes in peripheral blood, correlation with 
the MI-related or any other Axes of Variation were not strong. 
 An alternative multi-locus genotypic risk score for blood gene expression was 
generated by summing the number of alleles that are associated with expression of 
elevated expression in each of the Axes.  This score was generated using eSNP data from 
the parallel healthy adult cohort, and then applied to the Cardiology samples.  As 
expected, the scores are associated with the corresponding Axis scores, since individuals 
with more cases of elevated expression due to local regulatory polymorphisms will tend 
to have higher expression of genes in the relevant Axis overall. Compared to individual 
SNP effects on gene expression, the fraction of the covariance explained was lower. 
However, genotypic risk scores for Axis 1 and Axis 5 could be regarded as predictors of 
risk of MI in larger cohorts, since they were capable of differentiating the MI and non-MI 







Figure 8 A, B. Generic risk score of MI risk. 244 probes which are retained from 
ANOVA test with cardiac death index were used for generating genetic risk score. Risk 
allele is given risk score 2, risk score 1 for heterozygous, and risk score 0 for 






 The primary effort of this work was to find genomic evidence relevant to 
coronary artery disease. Two major methods of genomic analysis, gene expression 
profiling and GWAS on gene expression, were performed to dissect transcriptional and 
genotypic fingerprints of coronary artery disease. Blood-informative transcriptional Axes 
that can be described by 10 covariating transcripts per each Axis were utilized as a 
crucial measure of gene expression analysis.  
 This study of the relationship between gene expression variation and various 
measurements of coronary artery disease delivered compelling results showing strong 
association between two transcriptional Axes and incident of myocardial infarction. 244 
transcripts (Gene names provided in APPENDIX A) closely correlated with cardiac death 
were also showing clear association with those two transcriptional Axes. These results 
suggest potential transcripts for use in risk prediction for the advent of myocardial 
infarction and cardiac death.    
4.1 Correlation with Myocardial Infarction 
 This study produced evidence of clear signatures of myocardial infarction. First, 
the results show evidence that two Axes of variation, Axis1 and Axis5, are strongly 
associated with the MI diagnosis index. In general, about thousands of genes in each Axis 
from Preininger et al., represent consistently covariating pattern and 60% of total genes 
are corregulated with one of Axis. Axis1 and Axis5 are in turn enriched in aspects of 
activities of T-lymphocytes and Neutrophils. Since this cardiology cohort does not 
include information about cell count, enrichments of T-lymphocytes and Neutrophils 
activity were evaluated in the healthy Atlanta cohort from CHDWB and with genes 
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documented in the literature. Up-regulated Axis5 and down-regulated Axis1 were clearly 
observed with patients experiencing an MI. These signatures were not only revealed in 
phase1, but also discovered in phase2 of the CDGY cohort. While results from analysis 
of follow-up incidence of MI did not reach statistical significance, evident trends of high 
Axis5 and low Axis1 were detected both in phase1 and phase2. These outcomes are also 
consistent with the clinical data analysis done by Haumer et al., showing increased risk of 
major adverse cardiovascular events and death in the upper tertile of neutrophil counts 
and better cardiovascular outcome with lower tertile of lymphocyte counts [46]. In 
addition, recent re-analyses of the Framingham data by the Peter Wilson’s group at 
Emory University supported our results [47]. These findings lead us to conclude that 
there is a modification of the ratio of Neutrophils to Lymphocytes in MI patients, or that 
individuals with a high ratio are at higher risk of MI. 
 In addition to higher ratio of neutrophils to T-lymphocytes in MI patients, the 
alteration of genetic regulation on gene expression in patients with myocardial infarction 
demonstrates loss of the impact of genotypes on gene expression due to MI events. 
Comparison of cis regulating eSNP profiles for MI patients and non-MI patients in the 
cohort confirmed our two hypotheses: removal of MI patients increases the statistical 
significance of subset of eQTL and removal of people with high Axis5 alone (no MI) 
does not affect the eQTL profiles. These two analyses validated the hypothesis that 
altered genotypic regulation is not the result of enriched neutrophils circulating in the 
blood, but due to physiological changes in response to MI.  
 In conclusion, MI is associated not just with an increase in neutrophil activity, but 
also with an alteration of gene activity in both neutrophils and lymphocytes. While our 
results indicate that transcriptional changes are signatures of response to MI events, it is 
still not clear whether these differences between MI patients and the other groups were 
triggered due to response to the occurrence of MI or whether they are indicative of 
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predisposition to MI.  With longitudinal data, better clarification of cause and effect 
would be feasible.  
4.2 Predictive Transcripts of Cardiac Death 
 In this study, clustering with 244 unique transcripts was suggested as a risk 
predictor of cardiac death.  Expression of these transcripts and index of individuals whose 
deaths were caused by cardiovascular disease related event were strongly associated in 
phase1 of the CDGY cohort. These signatures of cardiac death were clearly revealed in 
phase 2 and follow-up cardiac death. Two-way hierarchical clustering of individuals with 
these transcripts produced 3 clearly defined groups in both phase 1 and phase2 as Figure6 
(A,B)  and most of patients who died from cardiovascular disease related event fell into a 
small cluster of 13 individuals showing down-regulated expression of 48% of the 244 
suggested transcripts. PC1 of suggested transcripts in phase1 which are correlated with 
confirmed death by cardiovascular disease were computed and PC1 shows significant 
association with cardiac death index and Acute MI event index. This is also observed 
with MI follow-up in phase1 (Figure 9). Not only within phase1, were theses strong 
association replicated in phase2. This replication study implies that PC1 of our suggested 
transcripts may contribute to predict MI risk which has not yet been occurred. Validation 
of these potential markers with larger data set will increase the power of assessment for 
cardiovascular disease.  
 PC1 of these genes was highly associated with increased activity in T-
lymphocytes and decreased activity in Neutrophils, implying that a higher ratio of 
Neutrophil activity to T-lymphocytes is suggestive evidence of elevated risk of cardiac 
death.  This outcome is consistent with correlation of Axis1 and Axis5 with myocardial 
infarction.  In addition to this, there was evidence showing that B cell activity was also 
enriched in the 244 transcripts annotation, indicating that pro-inflammatory responses are 





Figure 9 A, B, C, D, E. Association between Principal Component (PC) of cardiac death 
related transcripts and CAD status. (A) shows PC generated by 244 transcripts retained 
from ANOVA on cardiac death samples as y-axis. (B) is displaying the significant 
association of PC with Acute MI samples and (C) with MI follow up samples. The same 
plots were drawn in phase2 with cardiac death index (D) and Acute MI index (D). 244 
transcripts in phase1 were used to generate PC of transcripts in phase2.   
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4.3 Low Power of Follow-up Analysis and Ambiguities of Calling CAD Types 
 For the analyses with clinical data, it is crucial to have concrete definitions of 
criteria for diagnoses. Ambiguous classification of controls or degree of disease affects 
critical results of analyses and may give rise to loss of power of the study, and even lead 
to failure of an entire study. For example, participants who are classified as FINE can 
possibly have underestimated degrees of plaque accumulation, as measured by 
angiography examination. In this study, such an underestimation could hide signatures of 
association between the transcriptome and clinical measure of CAD. In order to avoid 
this, the criteria of classification for calling FINE or different disease types should be 
carefully addressed.    
 Unfortunately, the sample sizes of the CDGY cohorts are too small to evaluate 
whether genotypic differences contribute to the risk of cardiac death and myocardial 
infarction. The size of follow-up data is also limited in both phases of cohorts. Because of 
this, the power of replicated study was not reached to optimal power. Since our analyses 
are inferring that experiencing MI altered genotypic regulation of gene expression 
relevant to pro-inflammatory response, it is highly desirable to address whether 
genotypes also affect differentiation of gene expression in respect to coronary artery 
disease and advent of death to jointly contribute to develop robust genomic markers of 
risk of adverse events along with transcriptional peculiarity. Validation of predictive 
genomic markers with a larger number of samples may contribute as a new clinical tool 























































































































































































































































Lower principal component of 244 genes is suggested to be used as a genomic predictor 
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